CLINICAL TRIALS PROFILE FOR HALOFANTRINE HYDROCHLORIDE

All Clinical Trials for Halofantrine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00619944 ↗	Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir	Completed	University of Liverpool	Phase 4	2008-02-01	With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy. Current estimates are that 5-6 million people in sub-Saharan Africa require ART. At the same time, the World Health Organization (WHO) Roll Back Malaria campaign is aggressively promoting the use of artemether/lumefantrine as first-line therapy for malaria in this setting. Many patients in this setting have already become resistant to first-line ARV and have moved onto lopinavir/ritonavir (Kaletra) based second-line regimens. Kaletra is a potent inhibitor of Cytochrome P450 3A4 (CYP 3A4), an enzyme responsible for the metabolism of many drugs which is found predominantly in the liver and the gut. Lumefantrine, and to a lesser extent artemether, is extensively metabolized by CYP 3A4. Therefore when given to a patient already taking Kaletra for HIV, it is likely that elevated levels of these drugs in the patient will result. There is some concern that lumefantrine may be cardiotoxic due to its structural similarity to halofantrine which is known to cause irregular heart rhythms. This has not been borne out as yet in any studies performed with lumefantrine, however it is not known what levels will be achieved in patients when it is administered with a protease inhibitor such as Kaletra. The WHO has not addressed this issue in any of its previous policy documents but has identified ARV-antimalarial drug interaction studies as a research priority. This single dose pharmacokinetic (PK) study aims to compare the levels of lumefantrine/artemether that result when it is given to a patient on Kaletra with patients not on any ARV. Data generated by this study will help address this important knowledge gap which has been identified by WHO and others as meriting urgent investigation.
NCT00619944 ↗	Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir	Completed	Makerere University	Phase 4	2008-02-01	With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy. Current estimates are that 5-6 million people in sub-Saharan Africa require ART. At the same time, the World Health Organization (WHO) Roll Back Malaria campaign is aggressively promoting the use of artemether/lumefantrine as first-line therapy for malaria in this setting. Many patients in this setting have already become resistant to first-line ARV and have moved onto lopinavir/ritonavir (Kaletra) based second-line regimens. Kaletra is a potent inhibitor of Cytochrome P450 3A4 (CYP 3A4), an enzyme responsible for the metabolism of many drugs which is found predominantly in the liver and the gut. Lumefantrine, and to a lesser extent artemether, is extensively metabolized by CYP 3A4. Therefore when given to a patient already taking Kaletra for HIV, it is likely that elevated levels of these drugs in the patient will result. There is some concern that lumefantrine may be cardiotoxic due to its structural similarity to halofantrine which is known to cause irregular heart rhythms. This has not been borne out as yet in any studies performed with lumefantrine, however it is not known what levels will be achieved in patients when it is administered with a protease inhibitor such as Kaletra. The WHO has not addressed this issue in any of its previous policy documents but has identified ARV-antimalarial drug interaction studies as a research priority. This single dose pharmacokinetic (PK) study aims to compare the levels of lumefantrine/artemether that result when it is given to a patient on Kaletra with patients not on any ARV. Data generated by this study will help address this important knowledge gap which has been identified by WHO and others as meriting urgent investigation.
NCT00620438 ↗	Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients	Unknown status	Health Research Board, Ireland	Phase 4	2008-02-01	There are increasing numbers of HIV-infected patients in sub-Saharan Africa receiving antiretroviral drugs and/or rifampicin based antituberculous therapy. HIV infected patients are at an increased risk of contracting malaria. Increasing resistance to anti-malarials such as chloroquine, amodiaquine, fansidar, sulphadoxine-pyrimethamine in East and West Africa has led the WHO to recommend artemether-lumefantrine (Coartem®- Novartis) as first line therapy for malaria for adults and children. As early as 2004, fourteen countries in sub-Saharan Africa had adopted this guideline as national policy. There are no data on the interaction between Coartem® and any of the antiretroviral agents. Both components of Coartem® are substrates for the 3A4 isoform of cytochrome P450. Despite the lack of data, antiretroviral drugs and/or antituberculous drugs in addition to Coartem® are of necessity co-prescribed daily in the African setting. Nevirapine, efavirenz and rifampicin are known inducers of cytochrome P450 3A4. A technical consultation convened by WHO in June, 2004 concluded that additional research on interactions between antiretroviral and antimalarial drugs is urgently needed. We propose to perform a suite of pharmacokinetic studies to evaluate these interactions in HIV infected Ugandan patients. The aim of these studies is to evaluate the pharmacokinetic interaction between Coartem® and commonly co-prescribed inducers of 3A4 i.e. nevirapine, efavirenz and rifampicin. 1. Comparison of steady state pharmacokinetics of Coartem® in HIV-infected patients prior to commencement of nevirapine and at nevirapine steady state 2. Comparison of steady state pharmacokinetics of Coartem® in HIV-infected patients prior to commencement of efavirenz and at efavirenz steady state 3. Comparison of steady state pharmacokinetics of Coartem® in Ugandan patients at rifampicin steady state and without rifampicin

Clinical Trial Conditions for Halofantrine Hydrochloride

Condition Name

Condition Name for Halofantrine Hydrochloride
Intervention	Trials
HIV Infections	2
Falciparum Parasitaemia	1
Heart Failure	1

Condition MeSH

Condition MeSH for Halofantrine Hydrochloride
Intervention	Trials
Malaria	2
HIV Infections	2
Tuberculosis	1

Clinical Trial Locations for Halofantrine Hydrochloride

Trials by Country

Trials by Country for Halofantrine Hydrochloride
Location	Trials
Uganda	2
United Kingdom	2
France	1
Papua New Guinea	1

Clinical Trial Progress for Halofantrine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Halofantrine Hydrochloride
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Halofantrine Hydrochloride
Clinical Trial Phase	Trials
Completed	6
Unknown status	1

Clinical Trial Sponsors for Halofantrine Hydrochloride

Sponsor Name

Sponsor Name for Halofantrine Hydrochloride
Sponsor	Trials
University of Liverpool	2
Makerere University	2
University of Aberdeen	1

Sponsor Type

Sponsor Type for Halofantrine Hydrochloride
Sponsor	Trials
Other	14
Industry	2
U.S. Fed	2

Halofantrine Hydrochloride: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is halofantrine hydrochloride and what does the clinical record show?

Halofantrine hydrochloride is an antimalarial drug historically used for treatment of uncomplicated Plasmodium falciparum malaria. Clinical development is not active in the way it is for modern pipeline compounds. The available public record is dominated by older registration-era trials and subsequent safety- and stewardship-focused use rather than large, ongoing Phase 3 programs.

Current clinical status (publicly visible pattern):

• No ongoing late-stage global Phase 3 pivotal program is evident for halofantrine hydrochloride in the most standard trial registries typically used to track active development (e.g., ClinicalTrials.gov and major WHO-linked registries).
• The drug’s modern footprint is driven by policy and access decisions (where it is still authorized) and risk management rather than by new confirmatory efficacy trials.

What clinical trials exist in the modern trial landscape?

Clinical-trial visibility for halofantrine is characterized by:

• Older trials evaluating efficacy and parasitological clearance, often in uncomplicated malaria settings.
• Pharmacokinetic (PK) and interaction studies that address exposure variability and co-medication effects that matter for safety.
• Cardiac safety risk characterization (notably QT-related risk) that shaped labeling and constrained use.

Across the modern market-relevant period, the clinical story is less about efficacy replication and more about cardiac risk controls and drug interaction stewardship, which translates directly into lower commercial adoption versus partner regimens with more favorable safety profiles.

Why does halofantrine’s safety profile constrain development and market uptake?

Halofantrine is associated with QT prolongation risk. That risk has historically driven:

• Stringent dosing and patient selection norms.
• Avoidance of interacting drugs and cautious use in patients at elevated arrhythmia risk.
• Reduced preference relative to artemisinin-based combination therapies (ACTs), which dominate current uncomplicated P. falciparum treatment guidelines in most markets.

The practical consequence for business planning is that halofantrine’s commercial ceiling is structurally limited by:

• Lower willingness of regulators to expand indication breadth.
• Lower prescribing adoption by clinicians and public programs focused on guideline concordance.
• Higher operational burden for risk mitigation where stewardship infrastructure is limited.

---

How big is the halofantrine market today?

A precise, auditable “current-year global sales” figure for halofantrine is not reliably recoverable from public sources at the granularity needed for an investment-grade projection without mixing inconsistent datasets. The market is also not “broadly traded” in the way major antimalarial blockbusters are, which makes public earnings-based estimation less stable.

However, the market structure is clear from authorization and guideline dynamics:

• ACT-first guidelines for uncomplicated P. falciparum in most endemic regions.
• Halofantrine is typically treated as an older/limited option rather than a first-line mainstream therapy.
• Use persists in some settings due to availability history, procurement inertia, or constrained alternatives in specific geographies.

Market demand drivers (positive)

• Persisting malaria burden in regions with variable access to ACT supply.
• Situations where halofantrine is already stocked through procurement channels and replacement cycles lag.

Market demand constraints (negative)

• Guideline displacement by ACTs.
• Cardiac safety and drug interaction constraints that reduce willingness to adopt for routine uncomplicated malaria.
• Stewardship burden that can disfavor adoption in public health systems without robust monitoring.

---

What is the market outlook by region and use case?

Rather than a single global growth curve, halofantrine’s future depends on where it stays authorized and where it remains in procurement formularies.

Likely regional market patterns

• Regulatory and procurement inertia markets: Demand persists at modest levels where halofantrine is already present in national stock systems.
• Guideline-aligned markets: Limited or declining use due to ACT dominance and preference for safer regimens.

Likely use cases

• Uncomplicated P. falciparum where alternatives are constrained (supply, stockouts, or regimen access gaps).
• Contingency stocks in some public supply chains.

Key economics reality

Halofantrine is not positioned to capture incremental market share through trial-led label expansion. Its future market value is therefore more tied to:

• Continued authorization status, and
• Supply chain continuity, and
• Cost and procurement compatibility versus competing therapies.

---

What is the projection: revenues, volume, and timeline?

A forecast with explicit dollar figures requires a consistent baseline sales dataset, which is not available in a way that can be cited cleanly and compared across years. What can be projected from a business-planning standpoint is the directional demand trajectory and the quantitative allocation model used by realistic buyers.

Directional projection (base-case)

• 2026-2030: Flat to declining global demand due to ongoing ACT preference and safety stewardship pressure.
• 2030-2035: Further structural decline unless a procurement or authorization shock occurs that re-expands access.

Scenario model (volume)

Scenario	2026-2030 demand	2030-2035 demand	Business implication
Base case	Flat to down	Down	Treat as legacy/limited product, not a growth asset
Supply-constrained rebound	Temporary up	Flat	Episodic gains driven by access gaps
Authorization tightening	Down	Down	Material risk to procurement continuity
Rare procurement reversion	Stable	Slight up	Requires specific national policy shift

Commercial projection logic

• No new late-stage efficacy expansion means no label-driven demand acceleration.
• Safety constraints keep prescriber and program adoption limited.
• ACT competition keeps incremental market share hard to win.

---

What competitive alternatives will cap halofantrine’s upside?

Halofantrine competes in a therapeutic area where the market is dominated by ACTs and other modern antimalarial regimens with better safety and treatment adherence profiles. That competition matters because:

• Programs optimize for guideline compliance.
• Clinicians prefer regimens with lower cardiac monitoring needs.

In practice, halofantrine’s “edge” is historical availability rather than clinical superiority.

---

What should investors and R&D leaders watch next?

Near-term watch items that directly affect value:

• Policy and guideline updates in endemic country treatment protocols.
• National formulary changes and procurement tender outcomes.
• Regulatory action related to cardiac risk communications and contraindications.
• Supply chain reliability for halofantrine presentations already authorized.

Development watch item (low probability of value inflection):

• Any credible move toward new clinical evidence that could support a meaningful label expansion. Given the historical pattern, that is unlikely to create a market-turning advantage over ACT-first standards.

---

Key Takeaways

• Halofantrine hydrochloride is an established antimalarial with a modern development profile dominated by older efficacy and safety characterization rather than active late-stage programs.
• The market is constrained by QT-related safety risk and drug interaction stewardship, which limits adoption versus ACT-first standards.
• The demand outlook is flat to declining in the base case over 2026-2035, driven more by authorization and procurement continuity than by new clinical differentiation.
• Value hinges on regulatory status and tender cycle continuity, not on trial-led growth.

---

FAQs

1) Is halofantrine hydrochloride in active Phase 3 development now?

Publicly visible evidence shows no clear ongoing global late-stage pivotal program driving label expansion; the clinical record is dominated by historical trials and safety-oriented studies.

2) What is the main clinical reason halofantrine is not widely adopted today?

Cardiac risk, particularly QT prolongation, drives tighter patient selection and interaction controls and reduces routine prescribing in an ACT-first ecosystem.

3) What will most affect halofantrine demand in 2026-2030?

Procurement continuity, authorization status in specific endemic countries, and supply constraints for alternative therapies.

4) Can trial results reverse halofantrine’s market position?

A meaningful label expansion would require new, credible evidence that improves the benefit-risk profile relative to ACTs. The observable development pattern does not indicate this path.

5) Who are the key competitors that cap market share?

Dominant ACT regimens and other modern antimalarial treatments preferred under current treatment guidelines.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Halofantrine hydrochloride search results. https://clinicaltrials.gov/
[2] World Health Organization. Guidelines for malaria treatment and related policy documents. https://www.who.int/teams/global-malaria-programme/guidelines-for-malaria
[3] U.S. Food and Drug Administration. Drug safety communications and labeling resources relevant to antimalarial risk communications. https://www.fda.gov/